Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2022

View Archived Issues

PIK3C2B variants impact mTOR pathway and lead to lipid signaling-driven focal epilepsy

Cytokine promotes heart repair after infarct

Alpha-emitting radioimmunotherapy: using throrium-227 and antibody conjugates

CD47 blockade with 225Ac-anti-CD33 radioimmunoconjugate in acute myeloid leukemia

Magmas inhibition as new therapeutic strategy in medulloblastoma

Novel humanized mouse model of posterior fossa A ependymoma

New MRGPRX2 antagonists identified at Bioardis

Chengdu Baiyu Pharmaceutical describes G12C mutant GTPase KRAS inhibitors

2692372 Ontario, Dunad Therapeutics patent tubulin polymerization inhibitors

Anti-glypican-3 antibody-drug conjugates developed at Ardeagen

RP Scherer Technologies patents TROP-2-targeting antibody-drug conjugates

Studies explore asprosin as a target for treating binge eating

Lenire licenses VSN-16R from UCL for fragile X syndrome

Heterozygous mutations in TMEM163 cause hypomyelinating leukodystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...